代谢功能障碍相关脂肪性肝病相关肝细胞癌的表型
本文综述代谢功能障碍相关脂肪性肝病相关肝细胞癌的流行病学与疾病负担、发病机制、自然史、预后及治疗,并讨论代谢表型作为风险分层策略的作用以及高危患者识别与筛查策略的挑战和防治途径。
要点
- 代谢功能障碍相关脂肪性肝病已成为全球最常见的慢性肝病和肝细胞癌的主要原因之一。
- 相当比例的代谢功能障碍相关脂肪性肝病相关肝细胞癌可发生于无肝硬化的患者。
- 代谢表型可作为代谢功能障碍相关脂肪性肝病相关肝细胞癌风险分层的潜在策略。
核心结论
- 代谢功能障碍相关脂肪性肝病相关肝细胞癌可在无肝硬化患者中发生,其致癌具体通路尚未完全阐明。
- 代谢功能障碍相关脂肪性肝病患者的肝细胞癌监测建议具有挑战性。
- 定义涵盖关键病理生理特征的表型类别,有望促进特定代谢功能障碍相关脂肪性肝病相关肝细胞癌表型的识别并配套诊断与治疗策略。
研究设计与样本
- 本文为综述,讨论代谢功能障碍相关脂肪性肝病相关肝细胞癌的流行病学与医疗负担、机制数据、自然史、预后与治疗。
主要发现
- 代谢功能障碍相关脂肪性肝病(包括代谢功能障碍相关脂肪性肝炎)已成为全球最常见的慢性肝病和肝细胞癌的主要原因之一。
- 相当比例的代谢功能障碍相关脂肪性肝病相关肝细胞癌可发生于无肝硬化患者。
- 触发该情境下癌变的具体通路尚未完全阐明。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) typically develops as a consequence of liver cirrhosis, but HCC epidemiology has evolved drastically in recent years. Metabolic dysfunction-associated steatotic liver disease (MASLD), including metabolic dysfunction-associated steatohepatitis, has emerged as the most common chronic liver disease worldwide and a leading cause of HCC. A substantial proportion of MASLD-associated HCC (MASLD-HCC) also can develop in patients without cirrhosis. The specific pathways that trigger carcinogenesis in this context are not elucidated completely, and recommendations for HCC surveillance in MASLD patients are challenging. In the era of precision medicine, it is critical to understand the processes that define the profiles of patients at increased risk of HCC in the MASLD setting, including cardiometabolic risk factors and the molecular targets that could be tackled effectively. Ideally, defining categories that encompass key pathophysiological features, associated with tailored diagnostic and treatment strategies, should facilitate the identification of specific MASLD-HCC phenotypes. In this review, we discuss MASLD-HCC, including its epidemiology and health care burden, the mechanistic data promoting MASLD, metabolic dysfunction-associated steatohepatitis, and MASLD-HCC. Its natural history, prognosis, and treatment are addressed specifically, as the role of metabolic phenotypes of MASLD-HCC as a potential strategy for risk stratification. The challenges in identifying high-risk patients and screening strategies also are discussed, as well as the potential approaches for MASLD-HCC prevention and treatment.
引用
- Rivera-Esteban J, Muñoz-Martínez S, Higuera M, et al. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2024. PMID: 38604295. doi:10.1016/j.cgh.2024.03.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。